Viktor Roschke

Viktor Roschke has a diverse work experience in the biopharmaceutical industry. Viktor is the co-founder and CSO of Neuraly, Inc., a company focused on developing new drugs for neurodegenerative disorders. Viktor played a crucial role in corporate governance and fundraising, helping secure $36M in Series A funding. Before Neuraly, they co-founded Theraly Fibrosis, where they served as CEO and was involved in corporate governance and fundraising.

Prior to their entrepreneurial ventures, Roschke held positions at Zyngenia, Inc., where they served as Vice-President of Biopharmaceutical Research and Interim CEO, and Teva Pharmaceuticals, where they were Vice President of Biopharmaceutical Research. At CoGenesys, they held various roles, including Vice President of Pharmacology and Clinical Assays and Executive Director of Pharmacology and Clinical Assays. Viktor also worked at Human Genome Sciences, starting as a scientist and eventually becoming the Executive Director of Clinical Immunology and Antibody Development. In this role, they were responsible for new target discovery, reagent development, and therapeutic antibody development.

Overall, Roschke has a strong background in biopharmaceutical research, corporate governance, and fundraising, with a particular focus on neurodegenerative disorders and fibrotic diseases.

Viktor Roschke earned their PhD in Molecular Biology from Novosibirsk State University (NSU) in the period from 1972 to 1977.